Bellwether News in Biosimilars

Instant Humira to biosimilar conversions after CVS Health > Aetna > Caremark > Cordavis partners with Sandoz

Author

J.D. Kleinke
April 16, 2024

The reason why is seven paragraphs into the story. "Verticalization" has its benefits, and when it comes to drug company profits, if you can't beat 'em, BE them...

"In August 2023, CVS Health launched a new, wholly owned subsidiary called Cordavis to co-develop and commercialize biosimilar products in the U.S. At the time, the consumer healthcare giant said that its goal was to boost access to medicines and drive down prices by developing a robust portfolio of biosimilars that could foster more competition in the market. Cordavis’ first product is Hyrimoz, which it sells in partnership with Sandoz, at an 80% discount to Humira..."

Sandoz’s Biosimilar Skyrockets After CVS Removes AbbVie’s Humira from Formularies | BioSpace

Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.

www.biospace.com/article/sandoz-s-biosimilar-skyrockets-after-cvs-removes-abbvie-s-humira-from-formularies